ABT

Abbott Laboratories
D

ABT

Arincen83/100B

Abbott Laboratories balance sheet 1985–2026

Abbott Laboratories had 5.60B USD in cash and short-term investments on 30 June 2026, against total debt of 32.61B USD: net debt of 27.01B USD.

Total assets Total liabilities Shareholders' equity

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
Latest
Q2 FY2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Cash and equivalents
5.10B8.52B7.62B6.90B9.88B9.80B6.84B3.86B3.84B9.41B18.62B
Short-term investments
499.00M417.00M351.00M383.00M288.00M450.00M310.00M280.00M242.00M203.00M155.00M
5.60B8.94B7.97B7.28B10.17B10.25B7.15B4.14B4.09B9.61B18.78B
Cash growth
-23.06%+12.20%+9.45%-28.43%-0.77%+43.38%+72.66%+1.32%-57.48%-48.81%+206.53%
Receivables
8.60B7.93B6.93B6.57B6.22B6.49B6.41B5.43B5.18B5.25B3.25B
Inventory
7.32B6.49B6.19B6.57B6.17B5.16B5.01B4.32B3.80B3.60B2.43B
Other current assets
3.00B2.64B2.57B2.26B2.66B2.35B1.87B1.79B1.57B1.69B2.32B
Total current assets
24.52B26.00B23.66B22.67B25.22B24.24B20.44B15.67B14.63B20.15B26.78B
Property, plant and equipment
12.81B12.94B11.73B11.28B10.28B10.11B10.13B8.97B7.56B7.61B5.71B
Long-term investments
1.11B918.00M886.00M799.00M766.00M903.00M1.03B931.00M897.00M883.00M2.95B
Goodwill and intangibles
52.46B29.56B29.76B32.49B33.25B35.97B38.53B40.22B42.20B45.49B12.22B
Goodwill
35.24B24.04B23.11B23.68B22.80B23.23B23.74B23.20B23.25B24.02B7.68B
Intangible assets
17.21B5.53B6.65B8.82B10.45B12.74B14.78B17.03B18.94B21.47B4.54B
Other non-current assets
18.32B17.30B15.38B5.98B4.92B3.97B2.42B2.10B1.89B2.12B3.35B
Total assets
109.22B86.71B81.41B73.21B74.44B75.20B72.55B67.89B67.17B76.25B55.01B
Accounts payable
4.79B4.24B4.20B4.30B4.61B4.41B3.95B3.25B2.98B2.40B1.18B
Deferred revenue
0.000.000.000.000.000.000.000.000.000.000.00
Short-term debt
3.01B3.31B1.75B1.33B2.48B999.00M461.00M1.68B207.00M714.00M1.33B
Other current liabilities
0.005.54B5.91B6.13B6.50B5.77B5.72B4.47B4.34B4.30B3.22B
Total current liabilities
17.81B16.50B14.16B13.84B15.49B13.11B11.91B10.86B9.01B8.91B6.66B
Long-term debt
29.60B10.83B12.63B13.60B14.52B17.30B18.53B16.66B19.36B27.21B20.68B
Other non-current liabilities
10.04B3.73B4.46B4.78B4.74B5.74B6.06B6.18B6.02B7.02B4.25B
Lease obligations, current
0.000.000.000.000.000.000.000.000.000.000.00
Lease obligations, long-term
0.00931.00M896.00M949.00M943.00M956.00M902.00M755.00M0.000.000.00
Total liabilities
57.45B33.94B33.51B34.39B37.53B39.17B39.55B36.59B36.45B45.15B31.95B
Common stock and paid-in capital
25.50B25.53B25.15B24.87B24.71B24.47B24.15B23.85B23.51B23.21B13.03B
Retained earnings
49.79B49.78B47.26B37.55B35.26B31.53B27.63B25.85B24.56B23.98B25.57B
Accumulated other comprehensive income
-6.21B-6.00B-7.91B-7.84B-8.05B-8.37B-8.95B-8.47B-7.59B-6.06B-7.26B
Shareholders' equity
51.11B52.13B47.66B38.60B36.69B35.80B32.78B31.09B30.52B30.90B20.54B
Minority interest
652.00M641.00M237.00M224.00M219.00M222.00M219.00M213.00M198.00M201.00M179.00M
32.61B15.07B15.28B15.87B17.95B19.25B19.89B19.10B19.57B27.92B22.01B
Net cash
-27.01B-6.13B-7.31B-8.59B-7.78B-9.00B-12.74B-14.96B-15.48B-18.31B-3.23B
Working capital
6.70B9.50B9.50B8.83B9.74B11.13B8.53B4.80B5.62B11.24B20.12B
Book value per share
29.3229.8427.2722.0720.8020.0118.3617.4617.2517.6713.85
Tangible book value
-1.35B22.57B17.91B6.11B3.43B-168.00M-5.74B-9.13B-11.67B-14.60B8.32B
Tangible book value per share
-0.7712.9210.253.491.95-0.09-3.22-5.13-6.59-8.355.61
Current ratio
1.381.581.671.641.631.851.721.441.622.264.02
Debt to equity
0.640.290.320.410.490.540.610.610.640.901.07

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Common questions about Abbott Laboratories's cash and debt

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.